Plaque Psoriasis
📧 Sign up to get email alerts when something new happens for Plaque Psoriasis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2015-03-25FDA Approved: ENBREL — Supplemental Application (Immunex Corporation)
FDA approved a supplemental application for ENBREL (etanercept), expanding its label with additional indications. The submission status indi…
-
FDA approval · 2015-03-11FDA Approved: CALCIPOTRIENE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for CALCIPOTRIENE (calcipotriene) by Prasco Laboratories.
-
FDA approval · 2015-03-11FDA Approved: CALCIPOTRIENE — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application for CALCIPOTRIENE from Prasco Laboratories. This action supplements the original NDA020554 for t…
-
CLINICAL_TRIALS trial_result · 2015-02-20Clinical Trial Update: Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis [Phase 2]
A Phase 2 trial evaluating Apo805K1 in adults with moderate-to-severe chronic plaque psoriasis has completed, with results posted.
-
FDA approval · 2015-02-18FDA Approved: MOMETASONE FUROATE — Supplemental Application (Encube Ethicals, Inc.)
FDA approved a supplemental application for mometasone furoate from Encube Ethicals, Inc., granting approval of a supplemental ANDA for this…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-02-18Clinical Trial Update: Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis [Phase 2]
Novartis completed a Phase II efficacy study of a single-dose regimen of AIN457 for chronic plaque psoriasis. Results were posted in 2015.
-
CLINICAL_TRIALS trial_result · 2015-02-16Clinical Trial Update: A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis [Phase 2]
Phase 2 dose-ranging study of AIN457 (efalizumab) in adults with chronic plaque psoriasis has completed and posted results.
-
CLINICAL_TRIALS trial_result · 2015-02-10Clinical Trial Update: Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis [Phase 2]
A Phase 2 trial evaluating a multiple-loading dose regimen in patients with chronic plaque psoriasis has completed and posted results in 201…
-
CLINICAL_TRIALS trial_result · 2015-02-04Clinical Trial Update: Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluated adding modulators of homocysteine to adalimumab therapy for moderate to severe plaque psoriasis; the st…
-
FDA approval · 2015-01-21FDA Approved: COSENTYX — Original Application (Novartis Pharmaceuticals Corporation)
FDA approved the original Biologics License Application for Cosentyx (secukinumab) from Novartis Pharmaceuticals Corporation, establishing i…
-
CLINICAL_TRIALS trial_result · 2015-01-19Clinical Trial Update: Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis [Phase 3]
Phase 3 trial results update showing safety and efficacy of adalimumab in treating plaque psoriasis.
-
FDA approval · 2014-12-23FDA Approved: CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application for Calcipotriene and Betamethone Dipropionate submitted by Prasco Laboratories.
-
CLINICAL_TRIALS trial_result · 2014-12-18Clinical Trial Update: Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis [Phase 2]
This update reports completion of a Phase 2 dose-finding study of MT-1303 in adults with moderate to severe chronic plaque psoriasis.
-
CLINICAL_TRIALS trial_result · 2014-12-12Clinical Trial Update: Safety, Tolerability and Pharmacokinetics of MK-0873 Following Patch Application in Healthy Participants and Psoriasis Participants (MK-0873-020) [Phase 1]
Phase 1 study evaluating safety, tolerability and pharmacokinetics of MK-0873 after patch application in healthy participants and participan…
-
FDA approval · 2014-12-12FDA Approved: CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE — Original Application (Padagis Israel Pharmaceuticals Ltd)
FDA approved Padagis Israel Pharmaceuticals Ltd's original application for a calcipotriene and betamethasone dipropionate topical product, a…
-
CLINICAL_TRIALS trial_result · 2014-11-05Clinical Trial Update: Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis. [Phase 3]
Phase 3 trial update for oral apremilast (CC-10004) evaluating safety and effectiveness in moderate to severe plaque psoriasis; study comple…
-
CLINICAL_TRIALS trial_result · 2014-11-05Clinical Trial Update: Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis [Phase 3]
Phase 3 trial evaluating oral apremilast for moderate to severe plaque psoriasis has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2014-10-21Clinical Trial Update: Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis [Phase 2]
Phase 2 clinical trial evaluating safety and pharmacokinetics of apremilast in recalcitrant plaque psoriasis has completed with results post…
-
FDA approval · 2014-10-08FDA Approved: OTREXUP — Supplemental Application (Antares Pharma, Inc.)
FDA approved a supplemental application for OTREXUP (methotrexate) submitted by Antares Pharma, Inc.
-
FDA approval · 2014-09-30FDA Approved: HUMIRA — Supplemental Application (Cordavis Limited)
FDA approved Humira's supplemental application submitted by Cordavis Limited. The approval acts as a supplemental approval to the existing H…
-
CLINICAL_TRIALS research · 2014-09-25Clinical Trial Update: Quality of Life of Patients With Psoriasis Treated With Methotrexate: Prospective, Randomized, Double-blind, Parallel Group Study. [Phase 4]
A Phase 4, randomized, double-blind study evaluating quality of life in patients with severe plaque psoriasis treated with methotrexate in a…
-
FDA approval · 2014-09-23FDA Approved: HUMIRA — Supplemental Application (Cordavis Limited)
The FDA approved a supplemental application for Humira (adalimumab) to add Cordavis Limited as a supplier. This action supports continued av…
-
CLINICAL_TRIALS trial_result · 2014-09-19Clinical Trial Update: A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis [Phase 3]
Pfizer conducted a one-year Phase 3 trial to evaluate the effects and safety of CP-690,550 (tofacitinib) in adults with moderate to severe c…
-
FDA approval · 2014-09-19FDA Approved: OTEZLA — Supplemental Application (Amgen, Inc)
The FDA approved a supplemental application for OTEZLA (apremilast) submitted by Amgen.
-
CLINICAL_TRIALS trial_result · 2014-09-17Clinical Trial Update: An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation [Phase 4]
This Phase 4 open-label trial assessed the safety and effectiveness of adalimumab for moderate to severe plaque psoriasis in the Russian Fed…